VEG105192, 2010 trial summary    PDF trial summary

A randomised clinical trial investigating the effect of pazopanib versus placebo in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma

        Z

NCT00334282    Eur J Cancer 2013;49:1287-96  



Studied treatment
Control treatment



Patients treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma
Group sizes290 / 145
treatment line line 1+2
cross over



Blindness Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint PFS Design



EndpointX1N1X0N0TE95% CI OS - 290 - 145 0,91[0,71; 1,16] PFS - 290 - 145 0,46[0,34; 0,62]0,22,01,0

Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8     [PMID: 20100962]   link to pdf   add to Mendeley  

Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, Zarba JJ, Gladkov OA, Lee E, Szczylik C, McCann L, Rubin SD, Chen M, Davis ID A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013;49:1287-96     [PMID: 23321547]   link to pdf   add to Mendeley  

ClinicalTrial.gov record NCT00334282



Registering number NCT00334282 (see trial on clinicaltrials.gov)
Code Name